MyCondro™ the groundbreaking chondroitin sulfate

Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.

Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.

The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.

AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.

Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.

Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.

FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.

The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.